Mercury set for £235m launch, TLB set at 600bp

The next deal to launch in the European leveraged loan market — Cinven’s buy-out of Mercury Pharma — will offer a margin of 600bp on its term loan ‘B’, providing relief to institutional lenders worried that the double reverse flex on Bartec’s bullet tranche could start a drastic downward pricing trend.

  • 03 Sep 2012
Private equity firm Cinven is using £235m of senior loans to acquire UK pharmaceutical company Mercury Pharma, and has mandated HSBC, Jefferies, Lloyds and Mizuho to arrange the deal. The all-senior loan facilities include a £155m seven year term loan ‘B’ paying 600bp — a full percentage point ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 Bank of America Merrill Lynch (BAML) 6,415 22 12.84
2 Citi 5,781 17 11.57
3 BNP Paribas 3,530 14 7.06
4 Credit Suisse 2,783 8 5.57
5 Rabobank 2,633 4 5.27

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 99,251.11 279 13.17%
2 Bank of America Merrill Lynch 90,895.27 265 12.06%
3 Wells Fargo Securities 72,661.39 222 9.64%
4 JPMorgan 52,367.24 169 6.95%
5 Credit Suisse 41,885.89 127 5.56%